Armata Pharmaceuticals Inc (ARMP) Stock Price, Quote & News

Company Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 665 2928

Fax: 310 665 2963

Website: www.armatapharma.com

Address:

5005 McConnell Avenue, Los Angeles, United States

Trapped Nov. 14 at 7:55 PM

$ARMP up 10% on 100k shares. it’s ready to blow with the volume. let’s get it

0 · Reply

MoneyGroupLLC Nov. 14 at 6:53 PM

Enter: $ARMP Calls Strike Price: $8 Expiry Date: DEC 19 2025 Buy in Price: $0.44 - $3.70 Sell Price: $0.81 Profit : +85% (Turn every $1 into $1.85) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

King_of_the_bagholders Nov. 14 at 3:48 PM

$ARMP $CDTX

0 · Reply

King_of_the_bagholders Nov. 14 at 2:29 PM

$CDTX imagine having all those sell options on your plate this morning. Shorts are absolutely smoked. Check the spread on on $ARMP same shit

0 · Reply

Trapped Nov. 14 at 2:09 PM

$ARMP merck buy start up biotech for 10 billion. armp market cap under 300 million. let go. this is very undervalued!!! take a position and hold.

0 · Reply

MoneyGroupLLC Nov. 14 at 2:17 AM

Enter: $ARMP Calls Strike Price: $8 Expiry Date: DEC 19 2025 Buy in Price: $0.44 - $3.60 Sell Price: $0.84 Profit : +92% (Turn every $1 into $1.92) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Alex036 Nov. 13 at 10:47 AM

$ARMP pump the price to avoid falling too deep. such a simple puppeteer's strategy.

0 · Reply

MoneyGroupLLC Nov. 12 at 9:03 PM

Enter: $ARMP Calls Strike Price: $8 Expiry Date: DEC 19 2025 Buy in Price: $0.44 - $3.90 Sell Price: $0.95 Profit : +117% (Turn every $1 into $2.17) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Alex036 Nov. 12 at 5:50 PM

$ARMP Pong game here:)

0 · Reply

Trapped Nov. 11 at 9:25 PM

$ARMP low float low volume…moves on air. buy em up and wait 6 months like a smart investor would do. worth a lot more than 300 million.

0 · Reply

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

Nov 10, 2025, 7:00 AM EST - 4 days ago

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

Oct 22, 2025, 11:10 AM EDT - 23 days ago

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

Oct 14, 2025, 7:00 AM EDT - 4 weeks ago

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

Sep 8, 2025, 7:00 AM EDT - 2 months ago

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Sep 4, 2025, 7:00 AM EDT - 2 months ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:05 PM EDT - 3 months ago

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

May 19, 2025, 7:00 AM EDT - 6 months ago

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

May 14, 2025, 4:05 PM EDT - 6 months ago

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

May 1, 2025, 7:00 AM EDT - 7 months ago

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Mar 20, 2025, 5:56 PM EDT - 8 months ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

Mar 12, 2025, 5:08 PM EDT - 8 months ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

INVA

Mar 11, 2025, 7:00 AM EDT - 8 months ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Dec 19, 2024, 7:00 AM EST - 11 months ago

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Nov 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Nov 13, 2024, 4:05 PM EST - 1 year ago

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

Nov 12, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Structural Biology Publication

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Aug 15, 2024, 4:45 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Jul 10, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

May 7, 2024, 4:01 PM EDT - 1 year ago

Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update

Mar 21, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

Mar 4, 2024, 4:01 PM EST - 1 year ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

INVA

Feb 21, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

Nov 14, 2023, 4:00 PM EST - 2 years ago

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

May 31, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

May 11, 2023, 4:05 PM EDT - 2 years ago

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

Mar 16, 2023, 4:10 PM EDT - 2 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

Mar 6, 2023, 6:00 AM EST - 2 years ago

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

Jan 10, 2023, 4:05 PM EST - 3 years ago

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

INVA

Dec 22, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Nov 28, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

Nov 9, 2022, 4:15 PM EST - 3 years ago

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

Aug 1, 2022, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

May 23, 2022, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus

May 12, 2022, 4:17 PM EDT - 3 years ago

Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update

Mar 31, 2022, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva

INVA

Mar 17, 2022, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update

Mar 9, 2022, 1:00 PM EST - 4 years ago

HATCHspaces®, NexCore Group, and Nuveen Real Estate to Convert 56,300 SF Industrial Building to Biomanufacturing in West Los Angeles

Trapped Nov. 14 at 7:55 PM

$ARMP up 10% on 100k shares. it’s ready to blow with the volume. let’s get it

0 · Reply

MoneyGroupLLC Nov. 14 at 6:53 PM

0 · Reply

King_of_the_bagholders Nov. 14 at 3:48 PM

$ARMP $CDTX

0 · Reply

King_of_the_bagholders Nov. 14 at 2:29 PM

$CDTX imagine having all those sell options on your plate this morning. Shorts are absolutely smoked. Check the spread on on $ARMP same shit

0 · Reply

Trapped Nov. 14 at 2:09 PM

$ARMP merck buy start up biotech for 10 billion. armp market cap under 300 million. let go. this is very undervalued!!! take a position and hold.

0 · Reply

MoneyGroupLLC Nov. 14 at 2:17 AM

0 · Reply

Alex036 Nov. 13 at 10:47 AM

$ARMP pump the price to avoid falling too deep. such a simple puppeteer's strategy.

0 · Reply

MoneyGroupLLC Nov. 12 at 9:03 PM

0 · Reply

Alex036 Nov. 12 at 5:50 PM

$ARMP Pong game here:)

0 · Reply

Trapped Nov. 11 at 9:25 PM

$ARMP low float low volume…moves on air. buy em up and wait 6 months like a smart investor would do. worth a lot more than 300 million.

0 · Reply

MoneyGroupLLC Nov. 11 at 8:22 PM

Enter: $ARMP Calls Strike Price: $8 Expiry Date: DEC 19 2025 Buy in Price: $0.95 - $3.70 Sell Price: $1.50 Profit : +58% (Turn every $1 into $1.58) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Nov. 11 at 10:21 AM

Enter: $ARMP Calls Strike Price: $8 Expiry Date: DEC 19 2025 Buy in Price: $0.95 - $1.00 Sell Price: $2.15 Profit : +126% (Turn every $1 into $2.26) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Trapped Nov. 10 at 10:10 PM

$ARMP good news today. the LA facility is preparing for phase 3 which should start 2026. looking for FDA approval quickly.

0 · Reply

MoneyGroupLLC Nov. 10 at 8:55 PM

Enter: $ARMP Calls Strike Price: $8 Expiry Date: DEC 19 2025 Buy in Price: $0.95 - $1.50 Sell Price: $1.80 Profit : +90% (Turn every $1 into $1.90) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

King_of_the_bagholders Nov. 10 at 7:37 PM

$ARMP slow burn but printing nonetheless . Once it wakes up and folks zoom out it’s all over. Moving in fuckall volume. Super 🐂 ish

0 · Reply

Alex036 Nov. 10 at 7:15 PM

$ARMP Looks like these whales, instead of taking positions, built a ceiling over this rocket.

0 · Reply

Trapped Nov. 10 at 5:26 PM

$ARMP this stock can’t handle a lot of volume …even 100k shares on the buy side will catapult the pps. it’s simple. if a few whales were to take positions here , we be gone !!!

0 · Reply

DylanGFM Nov. 10 at 3:44 PM

$ARMP looking good on the daily $SWAG

0 · Reply

_www_larval_com_ Nov. 10 at 3:13 PM

$ARMP has reversed -10% lower to 1% (~47Kv) in the last few minutes, 11/21 options, follow for more volatility.

0 · Reply

History101 Nov. 10 at 3:10 PM

$ARMP trading halted, 10:10am eastern

0 · Reply

King_of_the_bagholders Nov. 10 at 2:41 PM

$ARMP

0 · Reply

MoneyGroupLLC Nov. 10 at 8:13 AM

Enter: $ARMP Calls Strike Price: $10 Expiry Date: DEC 19 2025 Buy in Price: $0.10 - $1.60 Sell Price: $0.14 Profit : +42% (Turn every $1 into $1.42) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Market Cap	242.38M
Revenue (ttm)	5.17M
Net Income (ttm)	-18.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-365.96%
Debt to Equity Ratio	-1.62

Volume	149,686
Avg Vol	326,806
Day's Range	N/A - N/A
Shares Out	36.23M
Stochastic %K	76%
Beta	1.16
Analysts	Sell
Price Target	$9.00